Harvard Bioscience misses top-line and bottom-line...

2026-05-12 07:38:35 ET More on Harvard Bioscience Harvard Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript Harvard Bioscience outlines 2026 guidance with 2%-4% revenue growth and high-margin focus following structural improvements Harvard Bioscience announces 1-for-10 reverse stock split Seeking Alpha's Quant Rating on Harvard Bioscience Read the full article on Seeking Alpha For further details see: Harvard Bioscience misses top-line and bottom-line estimates; initiates Q2 and reaffirms FY26 outlook